Open Access

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

  • Authors:
    • G. Perletti
    • V. Skerk
    • V. Magri
    • A. Markotic
    • S. Mazzoli
    • M. J. Parnham
    • F.M. E. Wagenlehner
    • K. G. Naber
  • View Affiliations

  • Published online on: August 25, 2011     https://doi.org/10.3892/mmr.2011.575
  • Pages: 1035-1044
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characteri­zed by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate; broad antibiotic but also biofilm-inhibiting properties; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.

Related Articles

Journal Cover

November-December 2011
Volume 4 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Perletti G, Skerk V, Magri V, Markotic A, Mazzoli S, Parnham MJ, Wagenlehner FE and Naber KG: Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review). Mol Med Rep 4: 1035-1044, 2011.
APA
Perletti, G., Skerk, V., Magri, V., Markotic, A., Mazzoli, S., Parnham, M.J. ... Naber, K.G. (2011). Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review). Molecular Medicine Reports, 4, 1035-1044. https://doi.org/10.3892/mmr.2011.575
MLA
Perletti, G., Skerk, V., Magri, V., Markotic, A., Mazzoli, S., Parnham, M. J., Wagenlehner, F. E., Naber, K. G."Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)". Molecular Medicine Reports 4.6 (2011): 1035-1044.
Chicago
Perletti, G., Skerk, V., Magri, V., Markotic, A., Mazzoli, S., Parnham, M. J., Wagenlehner, F. E., Naber, K. G."Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)". Molecular Medicine Reports 4, no. 6 (2011): 1035-1044. https://doi.org/10.3892/mmr.2011.575